Decoding the secrets of small extracellular vesicle communications: exploring the inhibition of vesicle-associated pathways and interception strategies for cancer treatment

被引:0
作者
Shams, Shams G. E. [1 ]
Ocampo, Ron-Joseph [1 ]
Rahman, Sanna [1 ]
Makhlouf, Maysoon M. [1 ]
Ali, Jihad [2 ]
Elnashar, Magdy M. [3 ]
Ebrahim, Hassan L. [1 ]
Abd Elmageed, Zakaria Y. [1 ]
机构
[1] Edward Via Coll Osteopath Med VCOM, Dept Biomed Sci, Discipline Pharmacol, 4408 Bon Aire Dr, Monroe, LA 71203 USA
[2] Medipol Univ, Sch Med, TR-34810 Istanbul, Turkiye
[3] Curtin Univ, Sch Med Pharm & Biomed Sci, Bentley, WA 6102, Australia
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2024年 / 14卷 / 05期
关键词
Small extracellular vesicles; cancer treatment; sEV inhibitors; clinical applications; PROTEOMIC ANALYSIS; EXOSOMES; CELLS; BIOGENESIS; DELIVERY; TSPAN8; GROWTH; CHEMORESISTANCE; RESISTANCE; CISPLATIN;
D O I
10.62347/JWMX3035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer disease is the second leading cause of death worldwide. In 2023, about 2 million new cancer cases and 609,820 cancer deaths are projected to occur in the United States. The driving forces of cancer progression and metastasis are widely varied and comprise multifactorial events. Although there is significant success in treating cancer, patients still present with tumors at advanced stages. Therefore, the discovery of novel oncologic pathways has been widely developed. Tumor cells communicate with each other through small extracellular vesicles (sEVs), which contribute to tumor-stromal interaction and promote tumor growth and metastasis. sEV-specific inhibitors are being investigated as a next-generation cancer therapy. A literature search was conducted to discuss different options for targeting sEV pathways in cancer cells. However, there are some challenges that need to be addressed in targeting sEVs: i) specificity and toxicity of sEV inhibitor, ii) targeted delivery of sEV inhibitors, iii) combination of sEV inhibitors with current standard chemotherapy to improve patients' clinical outcomes, and iv) data reproducibility and applicability at distinct levels of the disease. Despite these challenges, sEV inhibitors have immense potential for effectively treating cancer patients.
引用
收藏
页码:1957 / 1980
页数:24
相关论文
共 144 条
  • [1] Neoplastic Reprogramming of Patient-Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes
    Abd Elmageed, Zakaria Y.
    Yang, Yijun
    Thomas, Raju
    Ranjan, Manish
    Mondal, Debasis
    Moroz, Krzysztof
    Fang, Zhide
    Rezk, Bashir M.
    Moparty, Krishnarao
    Sikka, Suresh C.
    Sartor, Oliver
    Abdel-Mageed, Asim B.
    [J]. STEM CELLS, 2014, 32 (04) : 983 - 997
  • [2] Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells
    Adamus, Tomasz
    Hung, Chia-Yang
    Yu, Chunsong
    Kang, Elaine
    Hammad, Mohamed
    Flores, Linda
    Nechaev, Sergey
    Zhang, Qifang
    Gonzaga, Joanna Marie
    Muthaiyah, Kokilah
    Swiderski, Piotr
    Aboody, Karen S.
    Kortylewski, Marcin
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 27 : 611 - 620
  • [3] Methodologies to Isolate and Purify Clinical Grade Extracellular Vesicles for Medical Applications
    Akbar, Asma
    Malekian, Farzaneh
    Baghban, Neda
    Kodam, Sai Priyanka
    Ullah, Mujib
    [J]. CELLS, 2022, 11 (02)
  • [4] Nanogenomics and Artificial Intelligence: A Dynamic Duo for the Fight Against Breast Cancer
    Al-Sowayan, Batla S.
    Al-Shareeda, Alaa T.
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [5] Andreu Zoraida, 2023, Nanotheranostics, V7, P1, DOI 10.7150/ntno.73606
  • [6] Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells
    Antonyak, Marc A.
    Li, Bo
    Boroughs, Lindsey K.
    Johnson, Jared L.
    Druso, Joseph E.
    Bryant, Kirsten L.
    Holowka, David A.
    Cerione, Richard A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (12) : 4852 - 4857
  • [7] Arenz C, 2001, CHEMBIOCHEM, V2, P141, DOI 10.1002/1439-7633(20010202)2:2<141::AID-CBIC141>3.3.CO
  • [8] 2-G
  • [9] Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3
    Aung, Thiha
    Chapuy, Bjoern
    Vogel, Daniel
    Wenzel, Dirk
    Oppermann, Martin
    Lahmann, Marlen
    Weinhage, Toni
    Menck, Kerstin
    Hupfeld, Timo
    Koch, Raphael
    Truemper, Lorenz
    Wulf, Gerald G.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (37) : 15336 - 15341
  • [10] ESCRT-III: An endosome-associated heterooligomeric protein complex required for MVB sorting
    Babst, M
    Katzmann, DJ
    Estepa-Sabal, EJ
    Meerloo, T
    Emr, SD
    [J]. DEVELOPMENTAL CELL, 2002, 3 (02) : 271 - 282